The Top 5 Biosimilars Articles for the Week of June 15

Hi, I’m Skylar Jeremias for The Center for Biosimilars®, your resource for clinical, regulatory, business, and policy news in the rapidly changing world of biosimilars.

Here are the top 5 biosimilars articles for the week of June 15, 2020.

Number 5: Investigators reported an 88% overall response rate for a Sandoz rituximab biosimilar in combination with chemotherapy in patients with CD20-positive diffuse large B-cell lymphoma.

Number 4: In gaining FDA approval, Lannett’s insulin glargine product, Semglee, receives automatic status as a biologic under the Biologics Price Competition and Innovation Act (BPCIA) after being originally approved as a generic product. Semglee becomes the first insulin glargine to undergo this switch since the new rule change for insulins went into effect in March.

Number 3: Following in the footsteps of British Columbia, other Canadian provinces are working to implement their own biosimilars initiatives that would switch patients from some of the most costly reference biologics to biosimilar counterparts.

Number 2: In search of effective treatments for patients hospitalized with COVID-19, investigators will test an infliximab biosimilar called Remsima or CT-P13. They believe it may help to control cytokine release syndrome, which is associated with COVID-19 patients.

Number 1: The FDA has approved Pfizer’s pegfilgrastim biosimilar Nyvepria for use in lowering the incidence of infection as manifested by febrile neutropenia in patients with nonmyeloid malignancies receiving myelosuppressive anticancer drugs.

To read all of these articles and more, visit centerforbiosimilars.com.